4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Capricor Therapeutics, Inc. (CAPR) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 231 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CAPR reported $0M in revenue and ($105M) in net income.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $22M | $25M | $3M | — |
| Operating Income (EBIT) | ($108M) | ($43M) | ($24M) | ($30M) | — |
| Net Income | ($105M) | ($40M) | ($22M) | ($29M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($37M) | ($29M) | ($26M) | ($28M) | ($25M) | — |
| Net Income | ($34M) | ($30M) | ($25M) | ($26M) | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $356M | $170M | $59M | $50M | — |
| Total Liabilities | $50M | $25M | $36M | $38M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CAPR viewer.
About TickerBase · Data methodology & sources